Latest news:

Major milestone – Follicum successfully develops direct-to-scalp formulation to replace intradermal injections for first-in-class peptide-based FOL-005 hair loss drug candidate

Follicum AB (“Follicum” or “Company”) today announced that the company has developed a new cosmetically appealing direct-to-scalp formulation of its leading peptide drug candidate FOL-005 for topical treatment of hair loss which will be used in future clinical trials. In Follicum’s ongoing Phase IIa study, patients with hair loss are being treated with intradermal injections […]

Sign up for our Newsletter

Hair growth

Our drug candidate FOL-005 has, in clinical trials, demonstrated increased hair growth on healthy individuals

Read more


Follicums pre-clinical research has resulted in a new peptide, FOL-014, which increased the release of insulin on mice

Read more


We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more




29 Aug 18
LSX Nordic Congress

Follicum will participate, and present, at the LSX Nordic Congress in Stockholm 29-30 August 2018. L...

10 Sep 18
Nordic Life Science Days

Follicum will attend, and present, at the Nordic Life Science Days (NLSD) in Stockholm 10-12 Septemb...